fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Metronidazole & nystatin

All products: general benefit

Flagystatin · DIN 01926829 · 500 mg & 100000U · Vag suppository

General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Flagystatin · DIN 01926829 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Marketed since 2007-12-11 · brand FLAGYSTATIN · ATC G01AA51 NYSTATIN, COMBINATIONS · form Ovule · route Vaginal · ingredients METRONIDAZOLE 500 MG, NYSTATIN 100000 UNIT · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Flagystatin: Formulary list price $3.85 per unit (the source does not state the unit; exact figure $3.8510). What the ministry pays, not the patient.

Ministry pays: $3.8510 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01926829)

Source record
DIN 01926829: Flagystatin Raw flags: sec3=Y Item: 840416020; group id 831; item number 2024; lccId None; manufacturer id SAV Source form: Vag Sup; strength: 500mg & 100000U Recorded listing: General benefit Source prices (unrounded): $3.8510; ministry $3.8510 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926829 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12654
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (G01A): coverage varies; not interchangeable

  • Metronidazole (Noritate): general benefit, not a benefit
Other drugs in the same formulary class (84:04:16 Other Anti-Infectives) and how they are covered

Matched class: 84:04:16 Other Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: SILVER SULFADIAZINE Some products covered without a code (check the product listing): METRONIDAZOLE 84:04:16 Other Anti-Infectives

METRONIDAZOLE

· 5 products · General benefit (3), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 1%, 0.75%, 10% · Top Cr, Top Gel, Vag Cr-App

SILVER SULFADIAZINE

· 2 products · General benefit · strengths: 1% · Cr, Cr-50g Pk

POVIDONE - IODINE

· 2 products · Listed, not a benefit · strengths: 10% · Top Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:04:16
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:08 Fungicides, 84:04:12 Parasiticides Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. INDICATIONS FLAGYSTATIN (metronidazole and nystatin) is indicated for: • Mixed vaginal infection due to Trichomonas vaginalis and Candida albicans. FLAGYSTATIN has antibacterial and antifungal properties. To reduce the development of drug-resistant bacteria/fungi and maintain the effectiveness of FLAGYSTATIN and other antibacterial/antifungal drugs, FLAGYSTATIN should be used only to treat proven or strongly suspected mixed vaginal infections. 1.1. Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00085865.PDF PM date: 2026-08-21 Source product: FLAGYSTATIN; DIN 01926829; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.